Literature DB >> 33403887

Bioidentical hormones.

F Z Stanczyk1,2, H Matharu1, S A Winer1.   

Abstract

After the results of the Women's Health Initiative trials were published, patient and clinician interest in potential alternatives to conventional hormone therapy (HT) has grown. A commonly used alternative therapy involves custom-compounded steroid hormone preparations, formulated by compounding pharmacies. Many postmenopausal women consider the hormones as natural or bioidentical, in contrast to hormones used in conventional HT, which they consider synthetic. In actuality, the chemical structures of many of the hormones used in bioidentical HT (BHT) are the same as those used in conventional HT. To customize formulations, compounding pharmacies frequently use saliva testing to measure hormones. However, there is a misconception that salivary hormone levels are equivalent to non-protein-bound (free) hormones in blood. Because hormonal custom-compounded formulations are not approved by the Food and Drug Administration (FDA), there are concerns regarding their purity, potency, and quality. Evolving regulatory guidelines by the FDA on oversight of these products should lessen the concerns regarding their safety and efficacy. This review addresses important misconceptions and uncertainties pertaining to BHT, the relationship between salivary and serum/plasma steroid hormone concentrations, the effect of topical progesterone creams on the endometrium, the variability in custom-compounded steroid preparations, and FDA oversight of custom-compounded products.

Entities:  

Keywords:  Bioidentical; compounding; estrogens; postmenopause; progesterone; salivary testing

Year:  2021        PMID: 33403887     DOI: 10.1080/13697137.2020.1862079

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  1 in total

1.  Evaluation of an Anhydrous Permeation-Enhancing Vehicle for Percutaneous Absorption of Hormones.

Authors:  Guiyun Song; Daniel Banov; Hui Song; Yi Liu; Kendice Ip; August S Bassani; Benigno C Valdez
Journal:  AAPS PharmSciTech       Date:  2022-07-19       Impact factor: 4.026

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.